Abstract
The daily Covid-19 fatality rate is modelled with a trend line based on nominal day-to-day reproduction rates and a cosine to take account of weekly fluctuations. The fatality trajectory represented by this trend line can be projected from the number of daily infections by assuming a time lapse between symptom onset and death between 17 and 19 days and a nominal time-dependent fatality rate. The time trajectory of this fatality rate suggests a change of the infection dynamics at April 3, with an increase from 2.5% to 6% within 20 days perhaps indicating spread of infection to more vulnerable people. Later in summer, the nominal fatality rate decreases down to 1% in mid-July raising the question whether Covid-19 is intrinsically less lethal in summer. Although the time trajectories of infections and fatality are pronouncedly different, the reproduction rates obtained therefrom are similar indicating that the infection dynamics may reasonably well be deduced from the potentially biased reported infection rate if it is biased consistently, i.e. the same way, over an extended period of time. The administrative measures to contain the pandemic seem not to have an immediate effect on the infection dynamics but well the ease of restrictions. An effect of mask wearing on decreasing lethality cannot be excluded.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I use only publicly available data from the Robert Koch Institute. Approval is not necessary.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: Dieter.Mergel{at}Uni-Due.de
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
1
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos